These three biotech stocks should be outstanding long-term growth vehicles.
News & Analysis: Mirati Therapeutics
Around $36 billion worth of biopharma acquisitions over the past few years suggests smaller might be better.
It looks like a target considered undruggable is actually within reach.
Lackluster results from Amgen's KRAS inhibitor program are clearing a path for Mirati's candidate.
Investors cheered the biotech's plans to move its lead candidate forward.
Shares tumbled after the company reported clinical data from an important phase 2 trial. Here's what investors need to know.
These three biotechs will soon present clinical trial results that could send their share prices screaming in one direction or the other.
Wall Street cheers after the company announced favorable terms from a just-announced capital raise. Here's what investors need to know.
Over the past year, these two biotech stocks outperformed nearly all their peers. Can they keep it going?
Even though the market was higher, these stocks missed out. Find out why.